Neostem (NBS +5.7%) gets a boost from an upgrade at Aegis Capital with a Buy rating and a $2.50...


Neostem (NBS +5.7%) gets a boost from an upgrade at Aegis Capital with a Buy rating and a $2.50 price target. Aegis says NBS represents a unique participant in the stem cell sector, given the fact that it has four different technology platforms and a solid lead product candidate, AMR-001, which is a stem cell-based therapeutic for cardiovascular disease with tremendous potential. The drug is currently in a proof-of-concept Phase 2 trial that is slated to report data early next year, and positive results could land it a partnership with Baxter (BAX).

Comments (2)
  • bigkid53
    , contributor
    Comments (62) | Send Message
     
    From Aegis Capital's mouth to the market's ears!!
    24 Jun 2013, 02:34 PM Reply Like
  • iberia
    , contributor
    Comments (44) | Send Message
     
    Well, it's so nice to see the folks driving the share price a bit higher just because Aegis Corp suddenly discovered the huge potential of NBS... about one year after the stemcell community and SA readers. Amazing.
    Who's next? Shall we see another boost within the next few days?
    25 Jun 2013, 03:25 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs